201 related articles for article (PubMed ID: 26180920)
1. Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.
Yeo B; Zabaglo L; Hills M; Dodson A; Smith I; Dowsett M
Br J Cancer; 2015 Jul; 113(3):390-5. PubMed ID: 26180920
[TBL] [Abstract][Full Text] [Related]
2. The IHC4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?
Harel N; Cheema S; Williams D; Ireland-Jenkin K; Fancourt T; Dodson A; Yeo B
Asia Pac J Clin Oncol; 2021 Aug; 17(4):368-376. PubMed ID: 33567144
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
4. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
[TBL] [Abstract][Full Text] [Related]
5. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
[TBL] [Abstract][Full Text] [Related]
6. Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M
Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
Barton S; Zabaglo L; A'Hern R; Turner N; Ferguson T; O'Neill S; Hills M; Smith I; Dowsett M
Br J Cancer; 2012 May; 106(11):1760-5. PubMed ID: 22531639
[TBL] [Abstract][Full Text] [Related]
8. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
9. Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication.
Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK
J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Cheang MCU; Bliss JM; Viale G; Speirs V; Palmieri C; Shaaban A; Lønning PE; Morden J; Porta N; Jassem J; van De Velde CJ; Rasmussen BB; Verhoeven D; Bartlett JMS; Coombes RC;
Breast Cancer Res Treat; 2018 Feb; 168(1):169-178. PubMed ID: 29177605
[TBL] [Abstract][Full Text] [Related]
12. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
[TBL] [Abstract][Full Text] [Related]
13. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
[TBL] [Abstract][Full Text] [Related]
14. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
15. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A;
Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
17. IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.
Lakhanpal R; Sestak I; Shadbolt B; Bennett GM; Brown M; Phillips T; Zhang Y; Bullman A; Rezo A
Breast; 2016 Oct; 29():147-52. PubMed ID: 27498128
[TBL] [Abstract][Full Text] [Related]
18. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
19. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]